Quantitation of 4-cyclohexyl-2-hydroxy-3-(3-methylsulfanyl-2- [2-[(morpholine-4-carbonyl)amino]-3-phenylpropionylamino]propi onylamino ) butyric acid isopropyl ester (CP-80,794), a renin inhibitor, and its hydrolytic cleavage metabolite 2-[(morpholine-4-carbonyl)amino]-3-phenylpropionic acid (CP-84,364) in dog and human plasma by high-performance liquid chromatography.

Simple and precise high-performance liquid chromatographic (HPLC) assays were developed and validated for the determination of a renin inhibitor (RI), 4-cyclohexyl-2-hydroxy-3- (3-methylsulfanyl-2-[2-[(morpholine-4-carbonyl)amino]- 3-phenylpropionylamino]propionylamino)butyric acid isopropyl ester (CP-80,794, I), and its hydrolytic cleavage metabolite, 2-[(morpholine-4-carbonyl)amino]-3-phenylpropionic acid (CP-84,364, II) in dog and human plasma. The internal standard for I, CP-83,092 (III, a carbon-substituted derivative of I) and analyte were extracted by liquid-liquid extraction using n-butyl chloride, cleaved to form a fragment containing a primary amine, and subsequently fluorescently derivatized for measurement by HPLC. Samples were analyzed by reversed-phase HPLC using a Waters C18 column with fluorescence detection at 390 nm excitation/440 nm emission. The quantitation limit of I was 10 ng/ml and the calibration curve was linear over the range of 0.01-1.0 microgram/ml (r2 > 0.99). In dog and human plasma, intra- and inter-assay precision ranged from 2.3 to 16% and 3.0 to 18%, respectively. The average recoveries were similar (> or = 63%) for both I and III and the upper limit of quantification of I can be as high as 4 micrograms/ml. The internal standard for II, CP-96,452 (IV, a methoxy derivative of II) and analyte were extracted by anion-exchange solid-phase extraction and subsequent liquid-liquid extraction using methyl tert.-butyl ether. Samples were analyzed by reversed-phase HPLC using a Waters C18 column with ultraviolet detection at 214 nm. The quantitation limit of II was 20 ng/ml and the calibration curve was linear over the range of 0.02-2.0 micrograms/ml (r2 > 0.99). In dog and human plasma, intra- and inter-assay precision ranged from 2.6 to 13.0% and 1.8 to 20.0%, respectively. The average recoveries were similar (> or = 75%) for both II and IV and the upper limit of quantification of II can be as high as 20 micrograms/ml. The methods described have been successfully applied to the quantification of I and II in about 5000 dog and human plasma samples over a 2 year period.

High-performance liquid chromatographic analysis of the lactone and carboxylate forms of a topoisomerase I inhibitor (the antitumor drug GI147211) in plasma.

A sensitive reversed-phase high-performance liquid chromatographic method has been developed and validated for the quantitation of the lactone form (GI147211) of a topoisomerase I inhibitor and its carboxylate form (GI190421) from dog plasma. The method consists of two solid-phase extraction methods. The first method, referred to as the lactone-only method, utilizes a diol Bond Elut cartridge to separate the two forms and measures the lactone directly. The second method, referred to as the total method, converts the carboxylate form to the lactone through acidification of the plasma sample. Total lactone is then extracted from the sample using a C18 Bond Elut cartridge. The carboxylate is quantitated indirectly from the difference of the total and lactone-only. The range of the standard curve for the lactone-only method is 0.096-38.5 nM (0.05-20 ng/ml) and for the total method is 0.193-19.3 nM (0.1-10 ng/ml). This is the most sensitive method reported to date for a camptothecin analogue.